Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aris Mining Corp T.ARIS

Alternate Symbol(s):  T.ARIS.WT.A | CLGDF | ARMN | N.AMNG.NT.U

Aris Mining Corporation is a gold producer in the Americas. The Company is engaged in operating two mines with expansions underway in Colombia. The Segovia Operation is located in the Segovia-Remedios mining district in the department of Antioquia, Colombia, approximately 180 kilometers (km) northeast of Medellin. The Segovia Operations comprises four active underground gold mining operations, which include El Silencio, Sandra K, Providencia, and Carla. It has over 11 titles with a total area of 5,335.58 hectares (ha). The Marmato underground gold mine is located on the west side of the town of Marmato, in Marmato municipality of Caldas Department, in the Republic of Colombia, approximately 80 km from Medellin and 200 km northwest of the capital city of Bogota. The Company is also the operator and 51% owner of the Soto Norte Project, which is advancing to develop a new underground gold, silver and copper mine. In Guyana, it is advancing the Toroparu, a gold/copper project.


TSX:ARIS - Post by User

Bullboard Posts
Post by clinicaldatamanon Oct 18, 2016 2:52pm
73 Views
Post# 25357142

The CEO: Dr. Doogan..again in bold...

The CEO: Dr. Doogan..again in bold...The key here is the fact that this Portage Biotech is working on CNS indications...so i guess he knows his stuff


Dr. Doogan is a seasoned drug development executive and life sciences investor with more than 30 years experience in the global pharmaceutical industry. He joined Pfizer in 1982, where he held a number of senior positions in R&D in the USA, UK and Japan. Dr. Doogan was the clinical development head for what was to become ZOLOFT, an important antidepressant and one of the top selling products in the world.  He retired from Pfizer in 2007 as the Senior VP Head of World Drug Development. Subsequently Dr. Doogan was Head of R&D at Amarin where, along with the CEO, he raised $100m to fund the reorganization and portfolio realignment leading to completion of a Phase III program and NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides. During his career Dr. Doogan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the Boards of several biotechnology companies.
Bullboard Posts